Baxter International Inc Valuation – February 2016 $BAX
Benjamin Graham taught that Intelligent Investors must do a thorough fundamental analysis of investment opportunities to determine their intrinsic value and inherent risk.  This is best done by utilizing a systematic approach to analysis that will provide investors with a sense of how a specific company compares to another company or by reviewing the 10 Companies Benjamin Graham Would Invest In Today – February 2016. By using the ModernGraham method one can review a company’s historical accomplishments and determine an intrinsic value that can be compared across industries.  What follows is a stock analysis showing a specific look at how Baxter International Inc (BAX) fares in the ModernGraham valuation model.
Company Profile (obtained from Google Finance): Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.
[level-free]
To read the details of this valuation, you must be logged in as a premium member. If you are not a premium member, please consider becoming one.
Premium members can view a full ModernGraham valuation of the company and have access to download a PDF version of the valuation for easy reference. Here is a free sample valuation pdf, and here is a post detailing what can be found within each individual company’s valuation.
[/level-free]
[not-level-free]
Downloadable PDF version of this valuation:
Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?
What kind of Intelligent Investor are you?
| Defensive Investor; must pass 6 out of the following 7 tests. | ||||
| 1. Adequate Size of the Enterprise | Market Cap > $2Bil | $19,289,225,443 | Pass | |
| 2. Sufficiently Strong Financial Condition | Current Ratio > 2 | 1.86 | Fail | |
| 3. Earnings Stability | Positive EPS for 10 years prior | Pass | ||
| 4. Dividend Record | Dividend Payments for 10 years prior | Pass | ||
| 5. Earnings Growth | Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end | 24.96% | Fail | |
| 6. Moderate PEmg Ratio | PEmg < 20 | 10.86 | Pass | |
| 7. Moderate Price to Assets | PB Ratio < 2.5 OR PB*PEmg < 50 | 2.53 | Pass | |
| Score | ||||
| Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor. | ||||
| 1. Sufficiently Strong Financial Condition | Current Ratio > 1.5 | 1.86 | Pass | |
| 2. Sufficiently Strong Financial Condition | Debt to NCA < 1.1 | 0.74 | Pass | |
| 3. Earnings Stability | Positive EPS for 5 years prior | Pass | ||
| 4. Dividend Record | Currently Pays Dividend | Pass | ||
| 5. Earnings Growth | EPSmg greater than 5 years ago | Pass | ||
Stage 2: Determination of Intrinsic Value
| EPSmg | $3.31 |
| MG Growth Estimate | 0.33% |
| MG Value | $30.34 |
| Opinion | Overvalued |
| MG Value based on 3% Growth | $48.06 |
| MG Value based on 0% Growth | $28.17 |
| Market Implied Growth Rate | 1.18% |
| Current Price | $36.01 |
| % of Intrinsic Value | 118.68% |
Baxter International Inc qualifies for the Enterprising Investor but not the more conservative Defensive Investor.  The Defensive Investor is concerned with the low current ratio as well as the insufficient earnings growth over the last ten years.  The Enterprising Investor has no initial concerns. As a result, Enterprising Investors following the ModernGraham approach based on Benjamin Graham’s methods should feel comfortable proceeding with further research into the company.
As for a valuation, the company appears to be overvalued after growing its EPSmg (normalized earnings) from $3.24 in 2011 to an estimated $3.31 for 2015.  This level of demonstrated earnings growth does not support the market’s implied estimate of 1.18% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on Benjamin Graham’s formula, returns an estimate of intrinsic value below the price.
Stage 3: Information for Further Research
| Net Current Asset Value (NCAV) | -$2.20 |
| Graham Number | $23.06 |
| PEmg | 10.86 |
| Current Ratio | 1.86 |
| PB Ratio | 2.53 |
| Dividend Yield | 4.65% |
| Number of Consecutive Years of Dividend Growth | 0 |
[/not-level-free]
Useful Links:
| ModernGraham tagged articles | Morningstar |
| Google Finance | MSN Money |
| Yahoo Finance | Seeking Alpha |
| GuruFocus | SEC Filings |
Most Recent Balance Sheet Figures
| Balance Sheet Information | Sep2015 |
| Total Current Assets | $11,138,000,000 |
| Total Current Liabilities | $5,981,000,000 |
| Long-Term Debt | $3,791,000,000 |
| Total Assets | $20,172,000,000 |
| Intangible Assets | $4,128,000,000 |
| Total Liabilities | $12,348,000,000 |
| Shares Outstanding (Diluted Average) | 549,000,000 |
Earnings Per Share History
| Next Fiscal Year Estimate | $1.65 |
| Dec2014 | $4.56 |
| Dec2013 | $3.66 |
| Dec2012 | $4.18 |
| Dec2011 | $3.88 |
| Dec2010 | $2.39 |
| Dec2009 | $3.59 |
| Dec2008 | $3.16 |
| Dec2007 | $2.61 |
| Dec2006 | $2.13 |
| Dec2005 | $1.52 |
| Dec2004 | $0.63 |
| Dec2003 | $1.50 |
| Dec2002 | $1.66 |
| Dec2001 | $1.09 |
| Dec2000 | $1.25 |
| Dec1999 | $1.35 |
| Dec1998 | $0.55 |
| Dec1997 | $0.53 |
| Dec1996 | $1.23 |
Earnings Per Share – ModernGraham History
| Next Fiscal Year Estimate | $3.31 |
| Dec2014 | $4.01 |
| Dec2013 | $3.67 |
| Dec2012 | $3.60 |
| Dec2011 | $3.24 |
| Dec2010 | $2.88 |
| Dec2009 | $2.95 |
| Dec2008 | $2.42 |
| Dec2007 | $1.93 |
| Dec2006 | $1.55 |
| Dec2005 | $1.27 |
| Dec2004 | $1.17 |
| Dec2003 | $1.42 |
| Dec2002 | $1.31 |
| Dec2001 | $1.07 |
| Dec2000 | $1.04 |
| Dec1999 | $0.87 |
Recommended Reading:
Other ModernGraham posts about the company
Other ModernGraham posts about related companies
Disclaimer:
The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.
